The issue with using anti-cancer drugs such as gefitinib and erlotinib is the blood-brain barrier (BBB) permeability is not optimum for AD, but the EGFR inhibitors also showed neuroprotective potential in spinal cord injury [116]. The gene discussed is EGFR; the disease is Alzheimer disease.